Preclinical Studies Early preclinical studies in rodent obesity models demonstrated that AOD9604 administration reduced body weight and fat mass without affecting food intake, indicating a direct metabolic effect rather than an appetite-suppressing mechanism
Most notably, estrogen dips, which contributes to the loss of lean muscle mass and the increase of body fatespecially around the midsection
Adv Funct Mater 33:2209304 Kolate A, Baradia D, Patil S, Vhora I, Kore G, Misra A (2014) PEGa versatile conjugating ligand for drugs and drug delivery systems
metabolite Ac-LKKTE identified as potentially more active than parent compound Paradoxical finding: Both peptides show biological effects persisting hours to days after administration despite rapid plasma clearance Possible explanations: Tissue retention, active metabolites, or persistent signaling cascade activation Excretion Pathways Limited data exists on excretion for both peptides[22]: Likely renal elimination of peptide fragments Hepatic metabolism may contribute to clearance No accumulation detected in chronic dosing studies (animal models) Combined excretion kinetics have not been characterized in any species The disconnect between short plasma half-lives and prolonged biological effects represents a key area requiring mechanistic clarification for both individual peptides and their combination
Reported effects are generally mild and may include injection-site reactions (redness, soreness, swelling), nausea, stomach upset, headache, or fatigue
Many patients benefit from a combination approach, particularly when addressing both hormonal and metabolic goals simultaneously
